alexa Microbiome-induced Proteome Dysbiosis In Autoimmune Disease
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Trevor G Marshall
ScientificTracks Abstracts: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.002
Abstract
Even though chronic inflammatory disease often comprises 70% of a nation?s health budget, its molecular mechanisms have remained elusive. Without a clear pathogenic description, the available treatments for Autoimmune, Neurologic, and even psychiatric diagnoses, have remained marginally effective, and Preventative and Predictive Medicine has been stalled at the starting-gate. With Metagenomics came the understanding that man is a super-organism, a community of thousands of species of microbes functioning in homeostasis with the human genome. Proteomics and Metabolomics have built on this foundation with the knowledge that even seemingly similar diseases result from not a single transcriptional dysfunction, but from thousands of dysfunctional interactions between the host and its microbiome (the ?Interactome?). Molecular mimicry exists on a scale which was inconceivable just 5 years ago. Fortunately, the retargeting of an approved drug has allowed quick Translation of immunostimulative, rather than immunosuppressive therapies, resulting in a clinical paradigm shift, and improved opportunities for rapid molecular discovery.
Biography
Trevor G Marshall graduated from the University of Adelaide, South Australia, in 1974. His Doctoral thesis, ?Insulin metabolism in Diabetes,? was accepted by the University of Western Australia in 1985. He taught at the Institute of Technology in Lae, Papua New Guinea, Curtin University and the University of Western Australia, before moving to California in 1982. He is currently Director of the Autoimmunity Research Foundation in California. Research in the 1980?s led to successful therapies for cryptorchidism, male and female infertility, and diabetes, but he is best known for his recent discoveries in translational Metagenomics and Autoimmune disease. He has won US FDA designations for minocycline and clindamycin in the treatment of sarcoidosis, and is currently steering the new generic drug ?Pure Olmesartan? through FDA review. He is a Fellow of the European Association for Predictive, Preventive and Personalised Medicine (Brussels) and a member of the International Expert Council, Community of Practice: Preventative Medicine (Moscow).
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords